[{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Symbiosis Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Symbiosis Pharmaceutical Services \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Symbiosis Pharmaceutical Services \/ AstraZeneca"},{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"Enterome","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Symbiosis Pharmaceutical Services","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Symbiosis Pharmaceutical Services \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"7","companyTruncated":"Symbiosis Pharmaceutical Services \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"Clene Nanomedicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Symbiosis Pharmaceutical Services","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Suspension","sponsorNew":"Symbiosis Pharmaceutical Services \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"10","companyTruncated":"Symbiosis Pharmaceutical Services \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"MaaT Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"Symbiosis Pharmaceutical Services","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Rectal Enema","sponsorNew":"Symbiosis Pharmaceutical Services \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"10","companyTruncated":"Symbiosis Pharmaceutical Services \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"Paradox Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Antibody","year":"2025","type":"Financing","leadProduct":"LX-96","moa":"IgG","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Symbiosis Pharmaceutical Services","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Symbiosis Pharmaceutical Services \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"4","companyTruncated":"Symbiosis Pharmaceutical Services \/ Symbiosis Pharmaceutical Services"}]

Find Clinical Drug Pipeline Developments & Deals by Symbiosis Pharmaceutical Services

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The financing will be used to advance Paradox’s therapeutic pipeline, which includes LX-96, a monoclonal antibody designed for the treatment of late-stage immunoglobulin light chain (AL) amyloidosis.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          February 25, 2025

                          Lead Product(s) : LX-96

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Recipient : Paradox Immunotherapeutics

                          Deal Size : $10.0 million

                          Deal Type : Financing

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The proceeds will be used to file a new drug application under the accelerated approval pathway for CNM-Au8, a catalytically active gold nanocrystal suspension.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Undisclosed

                          January 10, 2024

                          Lead Product(s) : CNM-Au8

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II/ Phase III

                          Recipient : Clene Nanomedicine

                          Deal Size : $7.3 million

                          Deal Type : Public Offering

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Financing will be used to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel ‘OncoMimic’ cancer immunotherapy.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 25, 2020

                          Lead Product(s) : EO2401,Bevacizumab,Nivolumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Enterome

                          Deal Size : $52.6 million

                          Deal Type : Financing

                          blank

                          04

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial supply.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 22, 2020

                          Lead Product(s) : ChAdOx1 nCoV-19

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : AstraZeneca

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The funding will continue the clinical development of the company's current pipeline as well as the extension to other indications in oncology.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          May 02, 2020

                          Lead Product(s) : MaaT013

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Recipient : MaaT Pharma

                          Deal Size : $19.5 million

                          Deal Type : Series B Financing

                          blank